首页 > 最新文献

European journal of breast health最新文献

英文 中文
Overexpression of CDC25A, AURKB, and TOP2A Genes Could Be an Important Clue for Luminal A Breast Cancer. CDC25A、AURKB 和 TOP2A 基因的过度表达可能是 A 型乳腺癌的重要线索。
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-4-3
Murat Kaya, Asmaa Abuaisha, İlknur Süer, Melike Sultan Alptekin, Fahrünnisa Abanoz, Selman Emiroğlu, Şükrü Palanduz, Kıvanç Cefle, Şükrü Öztürk

Objective: Breast cancer (BC) is highly heterogeneous and one of the most common cancers. Luminal A (LUM A) is a subtype of BC with a better prognosis than other BC subtypes. The molecular mechanisms underlying the initiation and progression of the LUM A subtype are still unclear. Big data generated from microarray and sequencing systems can be re-analyzed, especially with the help of various in silico tools developed in recent years, and made applicable for in vitro and in vivo research. This work aimed to identify genes that may play a role in the progression of LUM A subtype of BC using both computational and laboratory-based methods.

Materials and methods: Overlapping genes associated with BC were identified from the The Cancer Genome Atlas database, GSE233242, GSE100925 geodata sets, and the geneshot tool. The network functional analysis between overlapping genes was determined with STRING 12.0. Expression levels of overlapping genes in BC were investigated with the TNMplot (https://tnmplot.com/analysis/) in silico tool. The effect of overlapping genes on the overall survival of LUM A cancer patients was defined using the Kaplan-Meier plotter tool. Expressions of genes identified using bioinformatics data were investigated via quantitative real-time -polymerase chain reaction (qRT-PCR) in LUM A tumor and adjacent tissue samples. The data were evaluated using the t-test. Both the sensitivity and specificity of selected genes have been determined using the receiver operating characteristic curve.

Results: In silico investigation showed that eleven genes were possibly associated with BC. Among them CDC25A, AURKB, and TOP2A were considerably increased in LUM A samples according to qRT-PCR results. An overall survival analysis also showed that overexpression of these three genes could reduce the overall survival of LUM A patients.

Conclusion: The genes CDC25A, AURKB, and TOP2A may play crucial functions in LUM A pathogenesis. Therapeutic strategies that diminish the expression of these connected genes may enhance the prognosis of LUM A patients.

目的:乳腺癌(BC)具有高度异质性,是最常见的癌症之一。腔隙 A 型(LUM A)是乳腺癌的一种亚型,其预后优于其他亚型。LUM A亚型发病和进展的分子机制尚不清楚。微阵列和测序系统产生的大数据可以重新分析,特别是借助近年来开发的各种硅学工具,使其适用于体外和体内研究。这项工作旨在利用计算和实验室方法,找出可能在LUM A亚型BC进展过程中发挥作用的基因:从癌症基因组图谱数据库、GSE233242、GSE100925 地理数据集和 geneshot 工具中确定了与 BC 相关的重叠基因。重叠基因之间的网络功能分析由 STRING 12.0 确定。使用 TNMplot (https://tnmplot.com/analysis/) 硅工具研究了 BC 中重叠基因的表达水平。使用 Kaplan-Meier plotter 工具确定了重叠基因对 LUM A 癌症患者总生存期的影响。通过实时聚合酶链反应(qRT-PCR)对 LUM A 肿瘤和邻近组织样本中利用生物信息学数据确定的基因表达进行了研究。数据采用 t 检验进行评估。使用接收者操作特征曲线确定了所选基因的敏感性和特异性:硅学调查显示,有 11 个基因可能与乳腺癌有关。根据 qRT-PCR 结果,其中 CDC25A、AURKB 和 TOP2A 在 LUM A 样本中显著增加。总生存率分析也显示,这三个基因的过度表达会降低 LUM A 患者的总生存率:结论:CDC25A、AURKB和TOP2A基因可能在LUM A发病机制中发挥关键作用。结论:CDC25A、AURKB 和 TOP2A 基因可能在 LUM A 发病机制中发挥关键作用,减少这些相关基因表达的治疗策略可能会改善 LUM A 患者的预后。
{"title":"Overexpression of <i>CDC25A, AURKB</i>, and <i>TOP2A</i> Genes Could Be an Important Clue for Luminal A Breast Cancer.","authors":"Murat Kaya, Asmaa Abuaisha, İlknur Süer, Melike Sultan Alptekin, Fahrünnisa Abanoz, Selman Emiroğlu, Şükrü Palanduz, Kıvanç Cefle, Şükrü Öztürk","doi":"10.4274/ejbh.galenos.2024.2024-4-3","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-4-3","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer (BC) is highly heterogeneous and one of the most common cancers. Luminal A (LUM A) is a subtype of BC with a better prognosis than other BC subtypes. The molecular mechanisms underlying the initiation and progression of the LUM A subtype are still unclear. Big data generated from microarray and sequencing systems can be re-analyzed, especially with the help of various <i>in silico</i> tools developed in recent years, and made applicable for <i>in vitro</i> and <i>in vivo</i> research. This work aimed to identify genes that may play a role in the progression of LUM A subtype of BC using both computational and laboratory-based methods.</p><p><strong>Materials and methods: </strong>Overlapping genes associated with BC were identified from the The Cancer Genome Atlas database, GSE233242, GSE100925 geodata sets, and the geneshot tool. The network functional analysis between overlapping genes was determined with STRING 12.0. Expression levels of overlapping genes in BC were investigated with the TNMplot (https://tnmplot.com/analysis/) <i>in silico</i> tool. The effect of overlapping genes on the overall survival of LUM A cancer patients was defined using the Kaplan-Meier plotter tool. Expressions of genes identified using bioinformatics data were investigated via quantitative real-time -polymerase chain reaction (qRT-PCR) in LUM A tumor and adjacent tissue samples. The data were evaluated using the t-test. Both the sensitivity and specificity of selected genes have been determined using the receiver operating characteristic curve.</p><p><strong>Results: </strong><i>In silico</i> investigation showed that eleven genes were possibly associated with BC. Among them <i>CDC25A, AURKB</i>, and <i>TOP2A</i> were considerably increased in LUM A samples according to qRT-PCR results. An overall survival analysis also showed that overexpression of these three genes could reduce the overall survival of LUM A patients.</p><p><strong>Conclusion: </strong>The genes <i>CDC25A, AURKB</i>, and <i>TOP2A</i> may play crucial functions in LUM A pathogenesis. Therapeutic strategies that diminish the expression of these connected genes may enhance the prognosis of LUM A patients.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"284-291"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reliability of L-Dex Scores for Assessment of Unilateral Breast Cancer-Related Lymphedema. 评估单侧乳腺癌相关淋巴水肿的 L-Dex 评分的可靠性
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-5-7
Leigh C Ward, Katrina Gaitatzis, Belinda Thompson, Vincent Singh Paramanandam, Louise A Koelmeyer

Objective: Breast cancer-related lymphedema (BCRL) is a common complication of breast cancer treatment that may result in swelling of the affected arm due to compromised lymphatic function. Implementing a screening program and early intervention for BCRL are important for effective management. Bioimpedance spectroscopy (BIS) is a commonly used tool for assessing BCRL. This study aimed to compare different normative ranges for BIS L-Dex scores in the detection of BCRL.

Materials and methods: Data from 158 women with clinically ascribed and indocyanine green confirmed BCRL were analysed. BIS measurements were obtained using an ImpediMed standing device, and L-Dex scores were calculated using published normative ranges for healthy individuals. Statistical analysis was performed to compare the concordance between different reference ranges in classifying individuals with lymphedema.

Results: The study found that L-Dex scores calculated using different normative ranges were highly correlated and essentially interchangeable in detecting BCRL. Approximately 90% of participants exceeded the L-Dex threshold for lymphedema, with minimal discrepancies between reference ranges. False negative rates were observed in some participants, likely due to early-stage BCRL with minimal lymph accumulation.

Conclusion: The findings suggest that BIS L-Dex scores are a valid indicator of BCRL, regardless of specific normative ranges used. Detection rates of clinically confirmed BCRL were consistent across different reference ranges, with minimal discrepancies. BIS remains a valuable tool for early detection and monitoring of BCRL. Future research should focus on longitudinal assessments and use of change in L-Dex scores for lymphedema monitoring and progression.

目的:乳腺癌相关淋巴水肿(BCRL)是乳腺癌治疗过程中常见的并发症,可能会因淋巴功能受损而导致患臂肿胀。实施乳腺癌相关淋巴水肿筛查计划和早期干预对有效治疗非常重要。生物阻抗光谱仪(BIS)是评估 BCRL 的常用工具。本研究旨在比较 BIS L-Dex 评分在检测 BCRL 时的不同标准范围:分析了 158 名经临床诊断和吲哚青绿证实为 BCRL 的妇女的数据。使用 ImpediMed 站立设备进行 BIS 测量,并使用已公布的健康人常模范围计算 L-Dex 分数。研究人员进行了统计分析,以比较不同参考范围在对淋巴水肿患者进行分类时的一致性:研究发现,采用不同常模范围计算出的 L-Dex 分数在检测 BCRL 方面具有高度相关性和基本互换性。约 90% 的参与者超过了淋巴水肿的 L-Dex 临界值,参考范围之间的差异极小。一些参与者出现了假阴性率,这可能是由于早期BCRL淋巴积聚极少所致:结论:研究结果表明,无论使用何种标准范围,BIS L-Dex 评分都是 BCRL 的有效指标。临床确诊 BCRL 的检出率在不同参考范围内保持一致,差异极小。BIS 仍是早期检测和监测 BCRL 的重要工具。未来的研究重点应放在纵向评估以及利用 L-Dex 评分的变化来监测淋巴水肿的发生和发展。
{"title":"Reliability of L-Dex Scores for Assessment of Unilateral Breast Cancer-Related Lymphedema.","authors":"Leigh C Ward, Katrina Gaitatzis, Belinda Thompson, Vincent Singh Paramanandam, Louise A Koelmeyer","doi":"10.4274/ejbh.galenos.2024.2024-5-7","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-7","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer-related lymphedema (BCRL) is a common complication of breast cancer treatment that may result in swelling of the affected arm due to compromised lymphatic function. Implementing a screening program and early intervention for BCRL are important for effective management. Bioimpedance spectroscopy (BIS) is a commonly used tool for assessing BCRL. This study aimed to compare different normative ranges for BIS L-Dex scores in the detection of BCRL.</p><p><strong>Materials and methods: </strong>Data from 158 women with clinically ascribed and indocyanine green confirmed BCRL were analysed. BIS measurements were obtained using an ImpediMed standing device, and L-Dex scores were calculated using published normative ranges for healthy individuals. Statistical analysis was performed to compare the concordance between different reference ranges in classifying individuals with lymphedema.</p><p><strong>Results: </strong>The study found that L-Dex scores calculated using different normative ranges were highly correlated and essentially interchangeable in detecting BCRL. Approximately 90% of participants exceeded the L-Dex threshold for lymphedema, with minimal discrepancies between reference ranges. False negative rates were observed in some participants, likely due to early-stage BCRL with minimal lymph accumulation.</p><p><strong>Conclusion: </strong>The findings suggest that BIS L-Dex scores are a valid indicator of BCRL, regardless of specific normative ranges used. Detection rates of clinically confirmed BCRL were consistent across different reference ranges, with minimal discrepancies. BIS remains a valuable tool for early detection and monitoring of BCRL. Future research should focus on longitudinal assessments and use of change in L-Dex scores for lymphedema monitoring and progression.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"251-257"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mastalgia and Why It Should Be Evaluated With Imaging in Areas Where Use of Breast Cancer Screening Services are Unsatisfactory. 乳腺增生症以及为何应在乳腺癌筛查服务不尽如人意的地区进行成像评估。
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-5-9
Shivangi Tomar, Akhilendra Singh Parihar, Sanjay Kumar Yadav, Rekha Agrawal

Objective: Mastalgia or breast pain is a very common symptom in women attending breast clinic. The aim of this study was to evaluate whether imaging for mastalgia leads to cancer detection in an area where routine breast cancer screening services are underutilized.

Materials and methods: This prospective study was performed between 1st March 2021 to 31st January 2023 at a tertiary care academic institution of central India. All patients underwent through clinical examination by a surgeon. Then patients were referred for ultrasound and/or X-ray mammography (MMG) depending on age. Cancer detection rate was calculated.

Results: The final cohort consisted of 176 patients with mastalgia and without any abnormality on clinical breast examination. Sixteen patients had mass lesion on radiology and core needle biopsy resulted as infiltrating duct carcinoma in 7 patients and benign phylloides tumor in one patient. Overall case detection rate for cancer was 4%.

Conclusion: The breast cancer detection rate in patients presenting with mastalgia was low. However, in the absence of routine mammographic screening in the Indian general population, these would have been missed. Hence, diagnostic assessment for mastalgia is an appropriate strategy in countries where routine screening MMG is lacking.

目的:乳痛症或乳房疼痛是乳腺门诊就诊妇女的常见症状。本研究的目的是评估在常规乳腺癌筛查服务利用率较低的地区,乳房疼痛的影像学检查是否会导致癌症的发现:这项前瞻性研究于 2021 年 3 月 1 日至 2023 年 1 月 31 日在印度中部的一家三级医疗学术机构进行。所有患者均由外科医生进行临床检查。然后,根据患者的年龄转介其接受超声波和/或 X 射线乳腺放射摄影(MMG)检查。计算癌症检出率:最终结果:176 名患者患有乳腺增生,临床乳房检查未见异常。16名患者在放射学检查中发现肿块病变,7名患者的核心针活检结果为浸润性导管癌,1名患者为良性植物瘤。癌症总检出率为 4%:结论:乳腺增生患者的乳腺癌检出率较低。结论:乳腺增生患者的乳腺癌检出率较低,但在印度普通人群中缺乏常规乳房 X 线照相筛查的情况下,这些患者可能会被漏诊。因此,在缺乏常规MMG筛查的国家,对乳腺痛进行诊断评估是一项适当的策略。
{"title":"Mastalgia and Why It Should Be Evaluated With Imaging in Areas Where Use of Breast Cancer Screening Services are Unsatisfactory.","authors":"Shivangi Tomar, Akhilendra Singh Parihar, Sanjay Kumar Yadav, Rekha Agrawal","doi":"10.4274/ejbh.galenos.2024.2024-5-9","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-9","url":null,"abstract":"<p><strong>Objective: </strong>Mastalgia or breast pain is a very common symptom in women attending breast clinic. The aim of this study was to evaluate whether imaging for mastalgia leads to cancer detection in an area where routine breast cancer screening services are underutilized.</p><p><strong>Materials and methods: </strong>This prospective study was performed between 1<sup>st</sup> March 2021 to 31<sup>st</sup> January 2023 at a tertiary care academic institution of central India. All patients underwent through clinical examination by a surgeon. Then patients were referred for ultrasound and/or X-ray mammography (MMG) depending on age. Cancer detection rate was calculated.</p><p><strong>Results: </strong>The final cohort consisted of 176 patients with mastalgia and without any abnormality on clinical breast examination. Sixteen patients had mass lesion on radiology and core needle biopsy resulted as infiltrating duct carcinoma in 7 patients and benign phylloides tumor in one patient. Overall case detection rate for cancer was 4%.</p><p><strong>Conclusion: </strong>The breast cancer detection rate in patients presenting with mastalgia was low. However, in the absence of routine mammographic screening in the Indian general population, these would have been missed. Hence, diagnostic assessment for mastalgia is an appropriate strategy in countries where routine screening MMG is lacking.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"258-261"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Use of Intralesional Corticosteroids in Idiopathic Granulomatous Mastitis: A Systematic Review. 在特发性肉芽肿性乳腺炎中使用皮质类固醇:系统综述。
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-5-2
Asel Wijesinghe, Kasun Lakmal, Jeewantha Senevirathna, Bhanu Wijetilake, J L T K Fernando, Umesh Jayarajah, Ajith De Silva, Kanchana Wijesinghe

Idiopathic granulomatous mastitis (IGM) is a debilitating, chronic, inflammatory condition of the breast. Several studies have emerged evaluating intralesional steroid (ILS) injection and topical steroid administration as a treatment for IGM. However, there is a dearth of international consensuses with regards to the management of IGM. Therefore, we have systematically reviewed the effectiveness of ILS in the management of IGM. A systematic search was conducted in PubMed and Cochrane Library databases, the Google Scholar website and by citation searching up to June 15th, 2023. Eight articles were selected and analyzed. A total of 397 IGM patients were included in the review. The mean patient age was 35.7 years, ranging from 23-62 years. The mean pre-treatment diameter of lesions was 27.5 mm. A total of 184 patients were treated with ILS. The mean complete clinical response time was 2.6 months. The overall complete response rate was 92.8%. Complications following ILS were minor, with hematoma, skin atrophy and hyperemia being commonly described, while avoiding the systemic side effects of oral steroid use, such as weight gain and hirsutism, which were the most commonly reported side effects with oral steroids. The recurrence rates in the ILS group (6.6%) appear to be lower than in the oral steroid group (25.8%) and surgery group (26.3%). ILS seem to show a favorable outcome in terms of complete response rate, complete clinical response time and has a lower recurrence rate and complication rate when compared to other intervention strategies. However, more comparative studies with standardized protocols are necessary to ascertain the optimum type, dosage and frequency of ILS regimens.

特发性肉芽肿性乳腺炎(IGM)是一种使人衰弱的慢性乳腺炎症。目前已有多项研究对局部注射类固醇(ILS)和局部使用类固醇治疗 IGM 进行了评估。然而,国际上对 IGM 的治疗缺乏共识。因此,我们对 ILS 治疗 IGM 的有效性进行了系统回顾。我们在 PubMed 和 Cochrane 图书馆数据库、谷歌学术网站上进行了系统检索,并在 2023 年 6 月 15 日前进行了引文检索。共筛选并分析了八篇文章。共有 397 名 IGM 患者被纳入研究。患者平均年龄为 35.7 岁,从 23 岁到 62 岁不等。治疗前病灶的平均直径为 27.5 毫米。共有 184 名患者接受了 ILS 治疗。平均完全临床反应时间为 2.6 个月。总体完全反应率为 92.8%。ILS 治疗后的并发症较少,常见的并发症有血肿、皮肤萎缩和充血,同时避免了口服类固醇药物的全身副作用,如体重增加和多毛症,而这些副作用是口服类固醇药物最常见的副作用。ILS 组的复发率(6.6%)似乎低于口服类固醇组(25.8%)和手术组(26.3%)。与其他干预策略相比,ILS似乎在完全反应率、完全临床反应时间、较低的复发率和并发症发生率等方面显示出良好的结果。然而,要确定 ILS 方案的最佳类型、剂量和频率,还需要进行更多标准化方案的比较研究。
{"title":"The Use of Intralesional Corticosteroids in Idiopathic Granulomatous Mastitis: A Systematic Review.","authors":"Asel Wijesinghe, Kasun Lakmal, Jeewantha Senevirathna, Bhanu Wijetilake, J L T K Fernando, Umesh Jayarajah, Ajith De Silva, Kanchana Wijesinghe","doi":"10.4274/ejbh.galenos.2024.2024-5-2","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-2","url":null,"abstract":"<p><p>Idiopathic granulomatous mastitis (IGM) is a debilitating, chronic, inflammatory condition of the breast. Several studies have emerged evaluating intralesional steroid (ILS) injection and topical steroid administration as a treatment for IGM. However, there is a dearth of international consensuses with regards to the management of IGM. Therefore, we have systematically reviewed the effectiveness of ILS in the management of IGM. A systematic search was conducted in PubMed and Cochrane Library databases, the Google Scholar website and by citation searching up to June 15th, 2023. Eight articles were selected and analyzed. A total of 397 IGM patients were included in the review. The mean patient age was 35.7 years, ranging from 23-62 years. The mean pre-treatment diameter of lesions was 27.5 mm. A total of 184 patients were treated with ILS. The mean complete clinical response time was 2.6 months. The overall complete response rate was 92.8%. Complications following ILS were minor, with hematoma, skin atrophy and hyperemia being commonly described, while avoiding the systemic side effects of oral steroid use, such as weight gain and hirsutism, which were the most commonly reported side effects with oral steroids. The recurrence rates in the ILS group (6.6%) appear to be lower than in the oral steroid group (25.8%) and surgery group (26.3%). ILS seem to show a favorable outcome in terms of complete response rate, complete clinical response time and has a lower recurrence rate and complication rate when compared to other intervention strategies. However, more comparative studies with standardized protocols are necessary to ascertain the optimum type, dosage and frequency of ILS regimens.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"233-240"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Flaxseed on Pain Relief and Quality of Life in Patients With Mastalgia: A Single Arm Interventional Study. 亚麻籽对乳腺增生患者疼痛缓解和生活质量的影响:单臂干预研究
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-6-2
Tabish Ansari, Priyanka Rai, Amarjot Singh, Rohit Srivastava, Sunil Singh, Vaibhav Raj Gopal

Objective: Mastalgia, a common complaint among women, denotes breast discomfort that can manifest as cyclical or non-cyclical. Reassurance, mechanical support and various non-pharmacological treatments, like flaxseeds, have been seen to have a good effect in treating mastalgia. Thus, the aim of this study was to investigates the efficacy of flaxseed in alleviating pain associated with mastalgia and its impact on the overall health-related quality of life among female patients.

Materials and methods: Conducted at a tertiary care center in Northern India over 18 months, it employed a single-arm interventional design. The participants included females aged 18 years and older presenting with breast pain at the Department of General Surgery. The intervention involved daily consumption of 30 g of milled flaxseed for each participant, administered over a period of six months. Pain severity was assessed using the visual analogue scale (VAS) before supplementation and at follow-up intervals up to six months. Concurrently, the Short Form-12 (SF-12) items Health Survey measured health-related quality of life, encompassing both physical and mental health domains. Statistical analysis employed parametric (paired t-test) and non-parametric tests (chi-square, McNemar) where appropriate, with statistical significance set at p<0.05.

Results: Two hundred women with mastalgia were included with a significant reduction in mean VAS scores from 6.03±0.83 at baseline to 2.19±0.66 at six months post-intervention (p = 0.0001). This reduction in pain intensity demonstrated a positive correlation with duration of flaxseed supplementation, notably declining after the initial three months. The mean difference in physical and mental SF-12 score at first visit and at 6 months after intervention was significant (p = 0.0001).

Conclusion: This study underscores the potential of flaxseed as a therapeutic option for managing mastalgia and enhancing health-related quality of life among affected individuals.

目的:乳房胀痛是女性的常见病,指乳房不适,可表现为周期性或非周期性。安抚、机械支持和各种非药物疗法(如亚麻籽)对治疗乳腺痛有良好效果。因此,本研究旨在调查亚麻籽对缓解乳腺增生相关疼痛的疗效及其对女性患者整体健康相关生活质量的影响:该研究在印度北部的一家三级医疗中心进行,历时 18 个月,采用单臂干预设计。参与者包括因乳房疼痛到普外科就诊的 18 岁及以上女性。干预措施包括每位受试者每天食用 30 克磨碎的亚麻籽,为期 6 个月。在补充亚麻籽之前和六个月的随访期间,使用视觉模拟量表(VAS)对疼痛的严重程度进行评估。同时,简表-12(SF-12)项目健康调查测量了与健康相关的生活质量,包括身体和心理健康领域。统计分析酌情采用参数检验(配对 t 检验)和非参数检验(秩和检验、McNemar 检验),统计显著性以 p 为限:200 名患有乳腺增生症的妇女接受了干预,其平均 VAS 分数从基线时的 6.03±0.83 显著降至干预后六个月时的 2.19±0.66(p = 0.0001)。疼痛强度的降低与补充亚麻籽的持续时间呈正相关,在最初的三个月后明显下降。首次就诊时和干预后 6 个月时,身体和精神 SF-12 评分的平均差异显著(p = 0.0001):这项研究强调了亚麻籽作为一种治疗选择的潜力,可用于控制乳腺增生并提高患者与健康相关的生活质量。
{"title":"Effect of Flaxseed on Pain Relief and Quality of Life in Patients With Mastalgia: A Single Arm Interventional Study.","authors":"Tabish Ansari, Priyanka Rai, Amarjot Singh, Rohit Srivastava, Sunil Singh, Vaibhav Raj Gopal","doi":"10.4274/ejbh.galenos.2024.2024-6-2","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-6-2","url":null,"abstract":"<p><strong>Objective: </strong>Mastalgia, a common complaint among women, denotes breast discomfort that can manifest as cyclical or non-cyclical. Reassurance, mechanical support and various non-pharmacological treatments, like flaxseeds, have been seen to have a good effect in treating mastalgia. Thus, the aim of this study was to investigates the efficacy of flaxseed in alleviating pain associated with mastalgia and its impact on the overall health-related quality of life among female patients.</p><p><strong>Materials and methods: </strong>Conducted at a tertiary care center in Northern India over 18 months, it employed a single-arm interventional design. The participants included females aged 18 years and older presenting with breast pain at the Department of General Surgery. The intervention involved daily consumption of 30 g of milled flaxseed for each participant, administered over a period of six months. Pain severity was assessed using the visual analogue scale (VAS) before supplementation and at follow-up intervals up to six months. Concurrently, the Short Form-12 (SF-12) items Health Survey measured health-related quality of life, encompassing both physical and mental health domains. Statistical analysis employed parametric (paired t-test) and non-parametric tests (chi-square, McNemar) where appropriate, with statistical significance set at <i>p</i><0.05.</p><p><strong>Results: </strong>Two hundred women with mastalgia were included with a significant reduction in mean VAS scores from 6.03±0.83 at baseline to 2.19±0.66 at six months post-intervention (<i>p</i> = 0.0001). This reduction in pain intensity demonstrated a positive correlation with duration of flaxseed supplementation, notably declining after the initial three months. The mean difference in physical and mental SF-12 score at first visit and at 6 months after intervention was significant (<i>p</i> = 0.0001).</p><p><strong>Conclusion: </strong>This study underscores the potential of flaxseed as a therapeutic option for managing mastalgia and enhancing health-related quality of life among affected individuals.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"303-308"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Predictive Role of Mammography, Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging and Diffusion-Weighted Imaging in Hormone Receptor Status of Pure Ductal Carcinoma In Situ Lesions. 乳腺放射摄影、动态对比增强乳腺磁共振成像和弥散加权成像对纯原位乳管癌病变的激素受体状态的预测作用。
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-5-1
Almıla Coşkun Bilge, Zarife Melda Bulut

Objective: The aim of this retrospective study was to analyze the predictive capabilities of preoperative mammography, dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI), and diffusion-weighted imaging (DWI) in determining hormone receptor (HRc) status for pure ductal carcinoma in situ (DCIS) lesions.

Materials and methods: The study included a total of 79 patients who underwent preoperative mammography (MG) and MRI between December 2018 and December 2023 and were subsequently diagnosed with pure DCIS after surgery. The correlation between MG, DCE-MRI, and DWI features and estrogen receptor (ER) and progesterone receptor (PR) status was examined.

Results: Among the lesions, 44 were double HRc-positive (ER and PR-positive), 13 were single HRc-positive (ER-positive and PR-negative or ER-negative and PR-positive) and 22 were double HRc-negative (ER and PR-negative). The presence of symptom (p = 0.029), the presence of comedo necrosis (p = 0.005) and high histological grade (p<0.001) were found to be associated with ER and PR negativity. Amorphous microcalcifications were more commonly observed in the double HRc-negative group, while linear calcifications were more prevalent in both double and single HRc-positive groups (p = 0.020). Non-mass enhancement (NME) with a linear distribution was significantly more common in double HRc-negative lesions (38%), and NME with a segmental distribution in both double (43%) and single (50%) receptor-positive lesions (p = 0.042). Evaluation of DWI findings revealed that a higher lesion-to-normal breast parenchyma apparent diffusion coefficient (ADC) ratio statistically increased the probability of HRc positivity (p = 0.033).

Conclusion: Certain clinicopathological, mammography, and MRI features, along with the lesion-to-normal breast parenchyma ADC ratio, can serve as predictors for HRc status in DCIS lesions.

研究目的这项回顾性研究旨在分析术前乳腺放射摄影、动态对比增强磁共振成像(DCE-MRI)和弥散加权成像(DWI)在确定纯导管原位癌(DCIS)病变的激素受体(HRc)状态方面的预测能力:研究纳入了2018年12月至2023年12月期间接受术前乳腺X线摄影(MG)和MRI检查、术后确诊为纯DCIS的共79例患者。研究人员考察了MG、DCE-MRI和DWI特征与雌激素受体(ER)和孕激素受体(PR)状态之间的相关性:病变中,44 例为双 HRc 阳性(ER 和 PR 阳性),13 例为单 HRc 阳性(ER 阳性和 PR 阴性或 ER 阴性和 PR 阳性),22 例为双 HRc 阴性(ER 和 PR 阴性)。存在症状(p = 0.029)、合并坏死(p = 0.005)和组织学分级高(pp = 0.020)。线性分布的非肿块强化(NME)在双 HRc 阴性病变中明显更常见(38%),而节段分布的非肿块强化在双受体阳性病变(43%)和单受体阳性病变(50%)中都更常见(p = 0.042)。对 DWI 结果的评估显示,病变与正常乳腺实质的表观弥散系数(ADC)比值越高,HRc 阳性的概率就越高(p = 0.033):结论:某些临床病理学、乳腺 X 线照相术和 MRI 特征以及病变与正常乳腺实质的 ADC 比值可作为 DCIS 病变 HRc 状态的预测指标。
{"title":"The Predictive Role of Mammography, Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging and Diffusion-Weighted Imaging in Hormone Receptor Status of Pure Ductal Carcinoma <i>In Situ</i> Lesions.","authors":"Almıla Coşkun Bilge, Zarife Melda Bulut","doi":"10.4274/ejbh.galenos.2024.2024-5-1","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-1","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this retrospective study was to analyze the predictive capabilities of preoperative mammography, dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI), and diffusion-weighted imaging (DWI) in determining hormone receptor (HRc) status for pure ductal carcinoma <i>in situ</i> (DCIS) lesions.</p><p><strong>Materials and methods: </strong>The study included a total of 79 patients who underwent preoperative mammography (MG) and MRI between December 2018 and December 2023 and were subsequently diagnosed with pure DCIS after surgery. The correlation between MG, DCE-MRI, and DWI features and estrogen receptor (ER) and progesterone receptor (PR) status was examined.</p><p><strong>Results: </strong>Among the lesions, 44 were double HRc-positive (ER and PR-positive), 13 were single HRc-positive (ER-positive and PR-negative or ER-negative and PR-positive) and 22 were double HRc-negative (ER and PR-negative). The presence of symptom (<i>p</i> = 0.029), the presence of comedo necrosis (<i>p</i> = 0.005) and high histological grade (<i>p</i><0.001) were found to be associated with ER and PR negativity. Amorphous microcalcifications were more commonly observed in the double HRc-negative group, while linear calcifications were more prevalent in both double and single HRc-positive groups (<i>p</i> = 0.020). Non-mass enhancement (NME) with a linear distribution was significantly more common in double HRc-negative lesions (38%), and NME with a segmental distribution in both double (43%) and single (50%) receptor-positive lesions (<i>p</i> = 0.042). Evaluation of DWI findings revealed that a higher lesion-to-normal breast parenchyma apparent diffusion coefficient (ADC) ratio statistically increased the probability of HRc positivity (<i>p</i> = 0.033).</p><p><strong>Conclusion: </strong>Certain clinicopathological, mammography, and MRI features, along with the lesion-to-normal breast parenchyma ADC ratio, can serve as predictors for HRc status in DCIS lesions.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"241-250"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applying the SOUND Trial for Omitting Axillary Surgery in Patients With Early Breast Cancer in Bahrain. 在巴林应用 SOUND 试验为早期乳腺癌患者省略腋窝手术。
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-5-11
Ali Hasan Abdulla, Reem Althawadi, Ahmed Zuhair Salman, Tareq Hamed Altaei, Amina Mohamed Mahdi, Hussain Adnan Abdulla

Objective: The Sentinel Node vs. Observation After Axillary Ultra-Sound (SOUND) trial reported that omission of axillary surgery was not inferior to sentinel lymph node biopsy (SLNB) in those with cT1 breast cancer and negative preoperative axillary ultrasound. The aim of our study was to evaluate the clinical characteristics of early breast cancer patients undergoing breast conserving surgery (BCS) at our institution in order to investigate the exportability of SOUND criteria to our patient population.

Materials and methods: We retrospectively reviewed patients with cT1N0 breast cancer undergoing BCS and adjuvant radiotherapy according to the SOUND trial criteria. Comparison was made between the eligible group of our cohort and the SLNB arm of the SOUND trial.

Results: The proportion of younger patients was higher in our eligible cohort (37.7% vs. 17.5%, p = 0.002). Postmenopausal patients were more prevalent in the SOUND trial (79.4% vs. 56.6%, p = 0.004). On final pathology, tumours were more likely to be upgraded to T2 in our group (26.4% vs. 4.4%, p = 0.001). Patients in our cohort were more likely to receive adjuvant chemotherapy (37.7% vs. 20.1%, p = 0.002).

Conclusion: The clinicopathological differences between our cohort and the SOUND trial population could be attributed to aggressive tumours in Bahrain compared to Western countries. Our study may influence others to investigate the applicability of the SOUND trial in clinical practice. Nevertheless, it is a study that should generate multidisciplinary discussion in the de-escalation of axillary surgery.

目的:前哨淋巴结与腋窝超声检查后观察(SOUND)试验报告显示,对于术前腋窝超声检查阴性的cT1乳腺癌患者,省略腋窝手术并不比前哨淋巴结活检(SLNB)效果差。我们的研究旨在评估本院接受保乳手术(BCS)的早期乳腺癌患者的临床特征,以研究 SOUND 标准在本院患者中的适用性:我们根据 SOUND 试验标准对接受 BCS 和辅助放疗的 cT1N0 乳腺癌患者进行了回顾性研究。我们将符合条件的组群与 SOUND 试验的 SLNB 组进行了比较:结果:在我们的合格组群中,年轻患者的比例更高(37.7% 对 17.5%,P = 0.002)。绝经后患者在 SOUND 试验中的比例更高(79.4% 对 56.6%,P = 0.004)。最终病理结果显示,我们组的肿瘤更有可能升级为T2(26.4% 对 4.4%,P = 0.001)。我们组的患者更有可能接受辅助化疗(37.7% vs. 20.1%,p = 0.002):结论:与西方国家相比,巴林的肿瘤具有侵袭性,这可能是我们的队列与 SOUND 试验人群之间存在临床病理学差异的原因。我们的研究可能会影响其他研究人员调查 SOUND 试验在临床实践中的适用性。尽管如此,这项研究仍应在腋窝手术降级方面引发多学科讨论。
{"title":"Applying the SOUND Trial for Omitting Axillary Surgery in Patients With Early Breast Cancer in Bahrain.","authors":"Ali Hasan Abdulla, Reem Althawadi, Ahmed Zuhair Salman, Tareq Hamed Altaei, Amina Mohamed Mahdi, Hussain Adnan Abdulla","doi":"10.4274/ejbh.galenos.2024.2024-5-11","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-11","url":null,"abstract":"<p><strong>Objective: </strong>The Sentinel Node vs. Observation After Axillary Ultra-Sound (SOUND) trial reported that omission of axillary surgery was not inferior to sentinel lymph node biopsy (SLNB) in those with cT1 breast cancer and negative preoperative axillary ultrasound. The aim of our study was to evaluate the clinical characteristics of early breast cancer patients undergoing breast conserving surgery (BCS) at our institution in order to investigate the exportability of SOUND criteria to our patient population.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed patients with cT1N0 breast cancer undergoing BCS and adjuvant radiotherapy according to the SOUND trial criteria. Comparison was made between the eligible group of our cohort and the SLNB arm of the SOUND trial.</p><p><strong>Results: </strong>The proportion of younger patients was higher in our eligible cohort (37.7% vs. 17.5%, <i>p</i> = 0.002). Postmenopausal patients were more prevalent in the SOUND trial (79.4% vs. 56.6%, <i>p</i> = 0.004). On final pathology, tumours were more likely to be upgraded to T2 in our group (26.4% vs. 4.4%, <i>p</i> = 0.001). Patients in our cohort were more likely to receive adjuvant chemotherapy (37.7% vs. 20.1%, <i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>The clinicopathological differences between our cohort and the SOUND trial population could be attributed to aggressive tumours in Bahrain compared to Western countries. Our study may influence others to investigate the applicability of the SOUND trial in clinical practice. Nevertheless, it is a study that should generate multidisciplinary discussion in the de-escalation of axillary surgery.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"270-276"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Patients Treated With Mastectomy: Indications for Treatment and Oncological Outcomes. 接受乳房切除术的乳腺癌患者新辅助化疗后的病理完全反应:治疗指征与肿瘤学结果
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-6-3
Corrado Tinterri, Shadya Sara Darwish, Erika Barbieri, Andrea Sagona, Valeriano Vinci, Damiano Gentile

Objective: The aim of this study was to evaluate the clinical outcomes of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) followed by mastectomy, focusing on cases achieving pathologic complete response (pCR). The implications of residual ductal carcinoma in situ (DCIS) on prognosis and survival were examined.

Materials and methods: A retrospective cohort study included BC patients treated with NAC followed by mastectomy at the breast unit of IRCCS Humanitas Research Hospital between March 2010 and October 2021. Patients were sub-grouped into two: Those with residual DCIS (ypTis) and those with complete response without residual tumor (ypT0). Key variables such as demographics, tumor characteristics, treatment regimens, and survival outcomes were analyzed.

Results: Of 681 patients treated with NAC, 175 achieved pCR, with 60 undergoing mastectomy. Among these 60 patients, 24 had residual DCIS (ypTis) while 36 had no residual invasive or in situ disease (ypT0). Patients with ypTis had higher rates of multifocal disease (62.5% vs. 27.8%, p = 0.006) and stage III disease (37.5% vs. 11.1%, p = 0.046). Triple-negative breast cancer was more prevalent in the ypT0 group (55.6% vs. 20.8%, p = 0.005). During a mean follow-up of 47 months, 11 patients experienced recurrence, with no significant differences in disease-free survival (DFS) and overall survival (OS) between the groups (p = 0.781, p = 0.963, respectively).

Conclusion: Residual DCIS after NAC did not significantly impact DFS or OS compared to complete pathologic response without residual DCIS. This study underscores the need for further research to refine pCR definitions and improve NAC's prognostic and therapeutic roles in BC management.

研究目的本研究旨在评估接受新辅助化疗(NAC)后进行乳房切除术的乳腺癌(BC)患者的临床疗效,重点关注获得病理完全反应(pCR)的病例。研究还探讨了残留导管原位癌(DCIS)对预后和生存的影响:这是一项回顾性队列研究,纳入了2010年3月至2021年10月期间在IRCCS Humanitas研究医院乳腺科接受NAC治疗并进行乳房切除术的BC患者。患者分为两组:有残留 DCIS 的患者(ypTis)和完全反应无残留肿瘤的患者(ypT0)。对人口统计学、肿瘤特征、治疗方案和生存结果等关键变量进行了分析:在接受 NAC 治疗的 681 名患者中,175 人获得了 pCR,其中 60 人接受了乳房切除术。在这60名患者中,24人有残留的DCIS(ypTis),36人没有残留的浸润性或原位疾病(ypT0)。ypTis 患者的多灶性疾病(62.5% 对 27.8%,p = 0.006)和 III 期疾病(37.5% 对 11.1%,p = 0.046)发生率较高。三阴性乳腺癌在ypT0组中发病率更高(55.6%对20.8%,p = 0.005)。在平均47个月的随访期间,11名患者复发,两组患者的无病生存期(DFS)和总生存期(OS)无显著差异(分别为p = 0.781和p = 0.963):结论:与无残留DCIS的完全病理反应相比,NAC术后残留DCIS对无病生存期和总生存期无明显影响。这项研究强调了进一步研究的必要性,以完善 pCR 定义并改善 NAC 在 BC 管理中的预后和治疗作用。
{"title":"Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Patients Treated With Mastectomy: Indications for Treatment and Oncological Outcomes.","authors":"Corrado Tinterri, Shadya Sara Darwish, Erika Barbieri, Andrea Sagona, Valeriano Vinci, Damiano Gentile","doi":"10.4274/ejbh.galenos.2024.2024-6-3","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-6-3","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to evaluate the clinical outcomes of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) followed by mastectomy, focusing on cases achieving pathologic complete response (pCR). The implications of residual ductal carcinoma <i>in situ</i> (DCIS) on prognosis and survival were examined.</p><p><strong>Materials and methods: </strong>A retrospective cohort study included BC patients treated with NAC followed by mastectomy at the breast unit of IRCCS Humanitas Research Hospital between March 2010 and October 2021. Patients were sub-grouped into two: Those with residual DCIS (ypTis) and those with complete response without residual tumor (ypT0). Key variables such as demographics, tumor characteristics, treatment regimens, and survival outcomes were analyzed.</p><p><strong>Results: </strong>Of 681 patients treated with NAC, 175 achieved pCR, with 60 undergoing mastectomy. Among these 60 patients, 24 had residual DCIS (ypTis) while 36 had no residual invasive or <i>in situ</i> disease (ypT0). Patients with ypTis had higher rates of multifocal disease (62.5% <i>vs</i>. 27.8%, <i>p</i> = 0.006) and stage III disease (37.5% <i>vs</i>. 11.1%, <i>p</i> = 0.046). Triple-negative breast cancer was more prevalent in the ypT0 group (55.6% <i>vs</i>. 20.8%, <i>p</i> = 0.005). During a mean follow-up of 47 months, 11 patients experienced recurrence, with no significant differences in disease-free survival (DFS) and overall survival (OS) between the groups (<i>p</i> = 0.781, <i>p</i> = 0.963, respectively).</p><p><strong>Conclusion: </strong>Residual DCIS after NAC did not significantly impact DFS or OS compared to complete pathologic response without residual DCIS. This study underscores the need for further research to refine pCR definitions and improve NAC's prognostic and therapeutic roles in BC management.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"277-283"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoaneurysm in the Axillary Tail of the Breast After A Core Needle Biopsy. 核心针活检后乳房腋尾的假性动脉瘤
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-4-5
Cedric Pluguez-Turull, Cinthia Del Toro, Nicole Brofman, Yara Z Feliciano

We present the case of a forty-year-old asymptomatic female with no personal or family history of breast cancer, who underwent a core needle biopsy (CNB) following the identification of a focal asymmetry in the right breast on screening mammography. Eight months later, a prominent adjacent vascular structure with a round outpouching was detected on breast ultrasound, confirmed as a post-biopsy pseudoaneurysm. Breast pseudoaneurysms, although exceedingly rare, result from inadvertent vessel puncture during core needle biopsies, particularly when larger gauge needles are used. They present as palpable, throbbing lumps in the breast and are well-defined heterogeneous structures that exhibit turbulent flow with a feeding artery on color Doppler imaging. This swirling sign showing a to-and-fro waveform is also known as the "yin-yang" sign on Doppler ultrasound. Post-CNB pseudoaneurysms in the breast, while rare, should be considered as potential complications following core need biopsy. Understanding their characteristic imaging features, risk factors, and available management options is essential for early diagnosis and appropriate treatment. This case underscores the importance of vigilance in biopsy procedures and the need for prompt recognition and intervention in case of such complications.

本病例是一名四十岁的无症状女性,无个人或家族乳腺癌病史,在乳房 X 光筛查中发现右侧乳房有局灶性不对称,随后接受了核心针活检(CNB)。八个月后,她在乳腺超声波检查中发现了一个突出的邻近血管结构,并伴有圆形外囊,证实为活检后假性动脉瘤。乳腺假性动脉瘤虽然极为罕见,但却是在核心针活检过程中不慎刺穿血管造成的,尤其是在使用较大规格的针头时。乳房假性动脉瘤表现为乳房内可触及的搏动性肿块,是界限清晰的异质结构,在彩色多普勒成像中表现为进血动脉的湍流。在多普勒超声检查中,这种显示往返波形的漩涡征也被称为 "阴阳 "征。乳腺核芯穿刺活检后假性动脉瘤虽然罕见,但应被视为核芯穿刺活检后的潜在并发症。了解假性动脉瘤的影像学特征、风险因素和可用的治疗方案对于早期诊断和适当治疗至关重要。本病例强调了在活检过程中保持警惕的重要性,以及在出现此类并发症时及时识别和干预的必要性。
{"title":"Pseudoaneurysm in the Axillary Tail of the Breast After A Core Needle Biopsy.","authors":"Cedric Pluguez-Turull, Cinthia Del Toro, Nicole Brofman, Yara Z Feliciano","doi":"10.4274/ejbh.galenos.2024.2024-4-5","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-4-5","url":null,"abstract":"<p><p>We present the case of a forty-year-old asymptomatic female with no personal or family history of breast cancer, who underwent a core needle biopsy (CNB) following the identification of a focal asymmetry in the right breast on screening mammography. Eight months later, a prominent adjacent vascular structure with a round outpouching was detected on breast ultrasound, confirmed as a post-biopsy pseudoaneurysm. Breast pseudoaneurysms, although exceedingly rare, result from inadvertent vessel puncture during core needle biopsies, particularly when larger gauge needles are used. They present as palpable, throbbing lumps in the breast and are well-defined heterogeneous structures that exhibit turbulent flow with a feeding artery on color Doppler imaging. This swirling sign showing a to-and-fro waveform is also known as the \"yin-yang\" sign on Doppler ultrasound. Post-CNB pseudoaneurysms in the breast, while rare, should be considered as potential complications following core need biopsy. Understanding their characteristic imaging features, risk factors, and available management options is essential for early diagnosis and appropriate treatment. This case underscores the importance of vigilance in biopsy procedures and the need for prompt recognition and intervention in case of such complications.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"313-315"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare Breast Emergency: A Case of Necrotizing Fasciitis of the Breast in a Lactating Patient. 罕见的乳房急症:哺乳期患者乳房坏死性筋膜炎病例。
IF 1.3 Q4 ONCOLOGY Pub Date : 2024-09-26 DOI: 10.4274/ejbh.galenos.2024.2024-5-10
Gökhan Giray Akgül, Sümeyra Güler, Simay Akyüz, Duygu Bayram, İbrahim Burak Bahçecioğlu, Müjdat Turan, Hikmet Erhan Güven, Mehmet Ali Gülçelik, Kerim Bora Yılmaz

Necrotizing fasciitis is a rare but potentially lethal infection of the skin and soft tissue, commonly seen in the perianal and gluteal regions. Concomitant diabetes is a predisposing factor. Primary necrotizing fasciitis of the breast is rare in healthy women. In this article, we present a very rare case of breast necrotizing fasciitis in the context of the literature. We report the case of a 35-year-old female patient who had given birth two months prior to admission and developed necrotizing fasciitis of the breast during lactation. The patient presented to the emergency department with sepsis. Examination revealed widespread erythema, dark discoloration, edema, and necrotic areas indicative of wet gangrene and crepitation in the left breast. Necrotizing fasciitis is a rapid and aggressive disease that can be fatal, and delayed diagnosis may unfortunately result in death. Therefore, careful evaluation of all suspected cases, especially for patients with risk factors, is crucial for early diagnosis and timely treatment. This case highlights the importance of recognizing necrotizing fasciitis of the breast in lactating women to ensure prompt and appropriate management, potentially saving lives.

坏死性筋膜炎是一种罕见但可能致命的皮肤和软组织感染,常见于肛周和臀部。糖尿病是易感因素之一。乳房原发性坏死性筋膜炎在健康女性中很少见。本文结合文献,介绍了一例非常罕见的乳腺坏死性筋膜炎病例。我们报告了一例 35 岁女性患者的病例,她在入院前两个月分娩,并在哺乳期患上了乳房坏死性筋膜炎。患者因败血症到急诊科就诊。检查发现左侧乳房有广泛的红斑、深色褪色、水肿和坏死区,表明左侧乳房有湿性坏疽和皱褶。坏死性筋膜炎是一种可致命的快速侵袭性疾病,延误诊断可能会导致患者死亡。因此,仔细评估所有疑似病例,尤其是有危险因素的患者,对于早期诊断和及时治疗至关重要。本病例强调了识别哺乳期妇女乳房坏死性筋膜炎的重要性,以确保及时和适当的治疗,从而挽救生命。
{"title":"Rare Breast Emergency: A Case of Necrotizing Fasciitis of the Breast in a Lactating Patient.","authors":"Gökhan Giray Akgül, Sümeyra Güler, Simay Akyüz, Duygu Bayram, İbrahim Burak Bahçecioğlu, Müjdat Turan, Hikmet Erhan Güven, Mehmet Ali Gülçelik, Kerim Bora Yılmaz","doi":"10.4274/ejbh.galenos.2024.2024-5-10","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2024.2024-5-10","url":null,"abstract":"<p><p>Necrotizing fasciitis is a rare but potentially lethal infection of the skin and soft tissue, commonly seen in the perianal and gluteal regions. Concomitant diabetes is a predisposing factor. Primary necrotizing fasciitis of the breast is rare in healthy women. In this article, we present a very rare case of breast necrotizing fasciitis in the context of the literature. We report the case of a 35-year-old female patient who had given birth two months prior to admission and developed necrotizing fasciitis of the breast during lactation. The patient presented to the emergency department with sepsis. Examination revealed widespread erythema, dark discoloration, edema, and necrotic areas indicative of wet gangrene and crepitation in the left breast. Necrotizing fasciitis is a rapid and aggressive disease that can be fatal, and delayed diagnosis may unfortunately result in death. Therefore, careful evaluation of all suspected cases, especially for patients with risk factors, is crucial for early diagnosis and timely treatment. This case highlights the importance of recognizing necrotizing fasciitis of the breast in lactating women to ensure prompt and appropriate management, potentially saving lives.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"20 4","pages":"309-312"},"PeriodicalIF":1.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European journal of breast health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1